Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
An 18-year-old noticed hairline retreat at 17.5 and is seeking advice on whether to accept baldness or try treatments like Minoxidil, finasteride, or RU58841. They are concerned about safety and effectiveness at their age.
DHT sensitivity at the scalp increases with age, contributing to androgenic alopecia. Treatments like Minoxidil, finasteride, and RU58841 are discussed for managing hair loss.
A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.
A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.
Hair loss treatments like finasteride and minoxidil are becoming more mainstream, with younger men starting early to prevent baldness. Increased sharing of transformations online and proactive approaches by Gen Z are contributing to noticeable changes.
DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
A 15-year-old is experiencing hair loss and is considering treatment options. They are aware they cannot use DHT blockers like finasteride due to their age and are exploring other causes like Telogen Effluvium.
A 23-year-old feels devastated by hair loss despite using Minoxidil and finasteride since age 18, and is advised to embrace baldness, improve physical fitness, and consider hair systems. The conversation emphasizes self-acceptance, confidence, and exploring new interests to improve mental well-being.
A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
Women also experience hair loss, especially post-menopause, often requiring lifestyle changes. Treatments include Scalp Micropigmentation, hair transplants, and sometimes finasteride, with underlying causes needing medical evaluation.
The user's experience with hair loss in their twenties and thirties, how to fix a receding hairline, treatments such as DHT, stress, bad sleep, Minoxidil, finasteride, and RU58841, and diet.
Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
The user experienced increased hair miniaturization and shedding despite using finasteride, topical minoxidil, microneedling, and other treatments. They are considering more aggressive treatments or a hair system if no improvement occurs by the end of 2025.
A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.
A 24-year-old woman with AGA and TE since age 14 is questioning if her hair is regrowing or breaking. She has been using minoxidil consistently since September 2025, along with caffeine and ketoconazole shampoos, rosemary oil, and saw palmetto, and has improved her overall hair care routine.
Stopping finasteride may reduce water retention or alter fat distribution, leading to a leaner face. Hormonal changes, like reduced DHT or increased estrogen, could cause these effects.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
The user experienced hair thinning and was diagnosed with alopecia incognito and male pattern baldness. They are using minoxidil, finasteride, and dutasteride scalp injections, reporting gradual improvement with no side effects.
A user started treating hair loss at 55 using 0.5 mg finasteride, 5% minoxidil every second day, and microneedling. They saw noticeable improvement, especially in the front and a previously smooth bald spot.
An 18-year-old noticed significant hairline recession and is concerned about further hair loss. They plan to improve their lifestyle and are advised to use finasteride and minoxidil and consult a dermatologist.
A 28-year-old male, who has been using minoxidil for 7 years, is concerned about hair miniaturization and is considering adding pyrilutamide, alfatradiol, and nizoral to his regimen after experiencing side effects from finasteride. Despite concerns, others reassure him that his hairline appears normal for his age, and he is likely around a Norwood 1.5.
Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.
Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Excessive sugar consumption may contribute to male pattern hair loss by increasing androgen sensitivity and insulin resistance, but genetics play a significant role. Treatments like minoxidil and finasteride are suggested for managing hair loss, while reducing sugar intake and maintaining a healthy lifestyle may help mitigate its progression.